Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeOur CompanyOur societal impact Global environmental sustainability

      Global environmental sustainability

      At Johnson & Johnson, we know that healthy people need a healthy planet.

      With our reach, expertise and convening power, we are taking action to positively impact planetary health and support the resilience of our business for generations to come.
      Expand
      We understand that environmental impacts are increasingly affecting people’s health and well-being, and that climate change is a global public health threat. We continually strive to improve the environmental footprint of our operations, our products and our value chain. Building on more than two decades of climate action, our current climate goals are our boldest yet, and our ambition is to reach net zero carbon emissions.


      As the world’s largest healthcare company, we also recognize our opportunity to drive positive change on issues that affect the health of the people we serve. Together with like-minded partners, we are working to tackle today’s global health challenges related to human and environmental health—issues like climate change and health equity.
      Collapse
      A sustainable power plant located on a peninsula surrounded by water
      At Johnson & Johnson, we care for the planet like our collective health depends on it … because it does.
      Paulette Frank
      Chief Sustainability Officer, Johnson & Johnson

      Our approach to environmental sustainability

      Our environmental sustainability work is aligned with our environmental, social and governance (ESG) strategy to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Advancing environmental health is key to our vision for a sustainable future and one of three areas where the Company is uniquely positioned to achieve the greatest impact – alongside championing global health equity and empowering our employees. Learn more about our ESG strategy.

      Everything we do at Johnson & Johnson is guided by Our Credo, written in 1943 by Robert Wood Johnson, which includes our commitment to “maintain in good order the property we are privileged to use, protecting the environment and natural resources.”

      Delivering more sustainable products and solutions

      We are committed to delivering the highest quality products for patients, doctors and consumers, while continually improving our environmental footprint.

      Advancing environmental health equity

      As the world’s largest healthcare company, we have a unique opportunity to look beyond our own operations and support people around the world who are experiencing the impacts of climate change on their physical and mental health.

      Latest news

      How Johnson & Johnson is working to create a healthier planet

      For World Health Day, learn about the rapid progress the company is making toward its commitment to creating a cleaner, safer environment around the globe.

      Johnson & Johnson named a 2023 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list.

      A commitment to social responsibility and innovation are just two of the attributes that helped the company land a spot on the prestigious list once again.

      Meet 3 Johnson & Johnson climate champions

      For Earth Day—and as Johnson & Johnson continues to make significant progress toward meeting its climate goals—learn about some of the employees who are working to impact both human health and the health of the planet.

      Johnson & Johnson Named a 2022 Fortune World’s Most Admired Company

      Learn how J&J landed on the global corporate reputation list for the 20th year in a row and ranked #1 on the Pharmaceutical Industry list for the ninth consecutive year.

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      How robots are helping personalize knee replacement surgery

      For Arthritis Awareness Month, learn the latest about this common procedure and how Johnson & Johnson MedTech is innovating to improve patient outcomes.

      Cautionary Note Regarding Forward-Looking Statements: This page contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the healthcare industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made on this page speaks only as of the date presented. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Third-party trademarks used herein are trademarks of their respective owners.

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.